The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.
Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.
Participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.
Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.
Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.
Individuals who have a history of frequent falls defined as more than 5 falls per month.
BioSensics
Lead sponsor
Johns Hopkins University
Collaborator
Massachusetts General Hospital
Collaborator
United States Department of Defense
Collaborator